Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01226368

Acronym

HP2V-AG

Enrollment

455

Registered

2010-10-22

Start date

2010-12-31

Completion date

2014-03-31

Last updated

2014-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1- Women, 2- HIV Infection, 3- Followed in West Indies and French Guiana for His Infection, 4- Acceptance of the Use of Nadis® Medical Files

Keywords

HIV, HPV, cervical-vaginal smear

Brief summary

Cervical cancer is a public health problem. In term of frequency and mortality, it represents in Martinique the third localization the most frequently diagnosed and the fifth cause of death by cancer. Cervical cancer is recognized as viro-inducted. Human papillomavirus (HPV) is the etiologic agent, as a necessary but not sufficient cause, in the cancer genesis. It is estimated than about 70 to 80% of women have been or will be infected with an HPV in their genital life, the risks factors being those of the others sexually transmitted diseases (STD). Most of HPV infection are transient, by spontaneous clearance in a few months of the virus under episomal form. Carcinogen risk is related to viral persistency which inducts the condition of cellular transformation. Infection persistency and subsequent carcinogen risk depend of the genotype concerned and of the host immunitary response. HIV infection is known to be associated with an higher prevalency of one or several infection with HPV-HR. However, no data about HIV/HPV coinfection prevalency are available nowadays in French overseas department of South America whereas they are the most affected by HIV.

Interventions

OTHERBiological Sample collection

Cervix cells

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women aged 18 years old or beyond * Infected with HIV1 or HIV2 * Follow up for HIV infection in one of the center participating in the study and acceptance of the use of Nadis® medical files * in one of the center participating in the study and acceptance of the use of Nadis® medical files within the context of follow up that should be realized according to the recommandation of undertaking: systematic Pap smear for asymptomatic patient s (expert's report, Pr.P.Yéni) or Pap smear for classical searching of any pathology of the uterine-cervix. * Acceptance of involvement into the study and collection of non opposition to the realization of HPV search from the sample realized for the Pap smear.

Exclusion criteria

* Women under age * History of total hysterectomy * Patient not followed for HIV infection in one of the center involved in the study * Patient that did not accept the use of Nadis® medical files * Impossibility to realize a Pap smear * Refusal of study's participation

Design outcomes

Primary

Measure	Time frame	Description
Presence of human papillomavirus	1 day	Presence of human papillomavirus in women's cervical smear infected with HIV and followed in West Indies and French Guiana

Secondary

Measure	Time frame	Description
Characterization of Human papillomavirus genotypes	1 day	Characterization of Human papillomavirus genotype found in women's cervical smear infected with HIV and followed in West Indies and French Guiana
Presence and the severity of cervical injuries.	1 day	—

Countries

Martinique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026